What is IPI Legacy Liquidation Co Earnings Power Value (EPV)?
As of Sep23, IPI Legacy Liquidation Co's earnings power value is $-4.82. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is
N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
IPI Legacy Liquidation Co Earnings Power Value (EPV) Historical Data
The historical data trend for IPI Legacy Liquidation Co's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IPI Legacy Liquidation Co Earnings Power Value (EPV) Chart
|
IPI Legacy Liquidation Co Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
| Earnings Power Value (EPV) |
|
- |
- |
- |
- |
|
IPI Legacy Liquidation Co Quarterly Data
|
|
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
| Earnings Power Value (EPV) |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of IPI Legacy Liquidation Co's Earnings Power Value (EPV)
For the Biotechnology subindustry, IPI Legacy Liquidation Co's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IPI Legacy Liquidation Co's Earnings Power Value (EPV) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IPI Legacy Liquidation Co's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where IPI Legacy Liquidation Co's Earnings Power Value (EPV) falls into.
IPI Legacy Liquidation Co Earnings Power Value (EPV) Calculation
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Business Description
Traded in Other Exchanges
N/A
Address
201 Elliott Avenue West, Suite 260, Seattle, WA, USA, 98119
Impel Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. The company is developing an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations.
Executives
| Vivo Capital Fund Viii, L.p. |
10 percent owner |
505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301 |
| Michael Wayne Kalb |
officer: CFO |
24 LUCILLE LANE, DIX HILLS NY 11746 |
| Darren S Cline |
director |
35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
| Rajiv Amin |
officer: VP, Controller & Interim CFO |
C/O IMPEL PHARMACEUTICALS INC., 201 ELLIOTT AVENUE WEST, STE 260, SEATTLE WA 98119 |
| Timothy S Nelson |
director |
1024 BUBB ROAD, CUPERTINO CA 950144166 |
| Adrian Adams |
director, officer: COB, CEO and President |
C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19355 |
| Venbio Global Strategic Fund Ii L.p. |
10 percent owner |
1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
| 5am Opportunities I, L.p. |
10 percent owner |
501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| 5am Opportunities I (gp), Llc |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| 5am Ventures V, L.p. |
10 percent owner |
2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025 |
| Kkr Healthcare Strategic Growth Fund L.p. |
10 percent owner |
C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019 |
| Norwest Venture Partners Xiv, Lp |
10 percent owner |
525 UNIVERSITY AVENUE, SUITE 800, PALO ALTO CA 94301 |
| Kkr Hcsg Gp Llc |
10 percent owner |
C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019 |
| 5am Partners V, Llc |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| Kkr Associates Hcsg L.p. |
10 percent owner |
C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019 |
IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IMPLQ has been successfully added to your